These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12618890)

  • 1. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Br J Cancer; 2003 Mar; 88(5):782-7. PubMed ID: 12618890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
    Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
    Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):571-2. PubMed ID: 12503818
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of capecitabine.
    Reigner B; Blesch K; Weidekamm E
    Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
    Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
    Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
    Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
    Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
    Desmoulin F; Gilard V; Malet-Martino M; Martino R
    Drug Metab Dispos; 2002 Nov; 30(11):1221-9. PubMed ID: 12386128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Minami H; Ebi H
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of the major metabolites of capecitabine.
    Gieschke R; Reigner B; Blesch KS; Steimer JL
    J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
    Nishida M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
    Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
    Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
    Twelves C; Glynne-Jones R; Cassidy J; Schüller J; Goggin T; Roos B; Banken L; Utoh M; Weidekamm E; Reigner B
    Clin Cancer Res; 1999 Jul; 5(7):1696-702. PubMed ID: 10430071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
    Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Morikawa A; Peereboom DM; Thorsheim HR; Samala R; Balyan R; Murphy CG; Lockman PR; Simmons A; Weil RJ; Tabar V; Steeg PS; Smith QR; Seidman AD
    Neuro Oncol; 2015 Feb; 17(2):289-95. PubMed ID: 25015089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
    Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
    Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
    Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.